ITG partners with leading U.S. manufacturers of advanced amniotic membrane allografts to deliver regenerative wound care across Asia, Latin America, and Europe — with the regulatory rigor, clinical support, and supply reliability serious markets require.
By bridging cutting-edge U.S. manufacturers with forward-thinking healthcare providers abroad, we enable faster healing, improved patient care, and expanded access to regenerative solutions. Whether you're a clinic in Buenos Aires or a hospital in Bangkok — we deliver the technology, evidence, and support to treat wounds with confidence and precision.
Direct access to U.S.-manufactured amniotic membrane allografts — with the regulatory documentation, clinical support, and reliable supply your patients deserve. Built for hospitals, clinics, and surgeons treating chronic and complex wounds.
Build a region-leading regenerative wound care portfolio with vetted, clinically-validated U.S. biologics. ITG offers prime distribution agreements with regulatory support, marketing tools, and clinical evidence behind every territory.
We distribute the most clinically-validated regenerative wound care platform in the world — SurGraft® dehydrated human amniotic membrane allografts. Three structural variants for chronic and complex wound applications, plus SurSight® for ophthalmic procedures.
The foundational dehydrated amniotic membrane allograft. Proven across chronic wound care, surgical applications, and complex tissue defects. 86–90% healing rates documented in chronic non-healing wounds.
Learn moreExtended-thickness and triple-layer constructs for the most challenging wound environments. Sufficient substance to be sutured, compatible with negative-pressure wound vacs.
Learn moreDehydrated amniotic membrane allograft purpose-formulated for corneal repair, reconstruction, and ophthalmic surgical applications including persistent epithelial defects and chemical burns.
Learn moreAcross published clinical studies and real-world outcomes data, the technologies we distribute consistently outperform conventional wound therapy — particularly in chronic ulcers where conventional care fails.
From Santiago to Sydney, Buenos Aires to Bangkok, Tokyo to Warsaw — ITG operates a vetted distribution network across markets where advanced regenerative wound care is most needed and most underserved.
From surgeons evaluating SurGraft® for chronic wound cases to in-country distributors building a regenerative wound care portfolio, ITG is built for the partnerships that change patient lives.
Get in Touch